Compugen Says Japanese Patent Office Granted Patent For Treating Cancer With Triple Combination Of Any Anti- PVRIG Antibody With Any Anti-TIGIT And Anti-PD-1 Antibody
Portfolio Pulse from Benzinga Newsdesk
Compugen announced that the Japanese Patent Office has granted a patent for treating cancer with a triple combination of any anti-PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody. This strengthens Compugen's patent portfolio and leadership in blocking three pathways of the DNAM-1 axis.
October 02, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of the patent in Japan for Compugen's triple combination cancer treatment strengthens its patent portfolio and could potentially increase its market share in the cancer treatment sector.
The granting of a patent for a new treatment method can potentially increase a company's market share and revenues as it provides a competitive edge. This is particularly true in the pharmaceutical industry where patents protect companies from competition and allow them to charge higher prices. Therefore, this news is likely to have a positive impact on Compugen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100